Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michelle Gellhorn-Serra"'
Autor:
Alexandra Kupke, Asisa Volz, Erik Dietzel, Astrid Freudenstein, Jörg Schmidt, Hosam Shams-Eldin, Sylvia Jany, Lucie Sauerhering, Verena Krähling, Michelle Gellhorn Serra, Christiane Herden, Markus Eickmann, Stephan Becker, Gerd Sutter
Publikováno v:
Vaccines, Vol 10, Iss 4, p 533 (2022)
The urgent need for vaccines against Ebola virus (EBOV) was underscored by the large outbreak in West Africa (2014–2016). Since then, several promising vaccine candidates have been tested in pre-clinical and clinical studies. As a result, two vacci
Externí odkaz:
https://doaj.org/article/c197fefc32064d6e8959d5b89150555f
Autor:
Sandro Halwe, Alexandra Kupke, Kanika Vanshylla, Falk Liberta, Henning Gruell, Matthias Zehner, Cornelius Rohde, Verena Krähling, Michelle Gellhorn Serra, Christoph Kreer, Michael Klüver, Lucie Sauerhering, Jörg Schmidt, Zheng Cai, Fei Han, David Young, Guangwei Yang, Marek Widera, Manuel Koch, Anke Werner, Lennart Kämper, Nico Becker, Michael S. Marlow, Markus Eickmann, Sandra Ciesek, Felix Schiele, Florian Klein, Stephan Becker
Publikováno v:
Viruses, Vol 13, Iss 8, p 1498 (2021)
Despite the recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the g
Externí odkaz:
https://doaj.org/article/a952a8244dfc4b74bafbb2519784edf5
Autor:
Aileen Ebenig, Samada Muraleedharan, Julia Kazmierski, Daniel Todt, Arne Auste, Martina Anzaghe, André Gömer, Dylan Postmus, Patricia Gogesch, Marc Niles, Roland Plesker, Csaba Miskey, Michelle Gellhorn Serra, Angele Breithaupt, Cindy Hörner, Carina Kruip, Rosina Ehmann, Zoltan Ivics, Zoe Waibler, Stephanie Pfaender, Emanuel Wyler, Markus Landthaler, Alexandra Kupke, Geraldine Nouailles, Christine Goffinet, Richard J.P. Brown, Michael D. Mühlebach
Vaccine-associated enhanced respiratory disease (VAERD) is a severe complication for some respiratory infections. To investigate the potential for VAERD induction in coronavirus disease 2019 (COVID-19), we evaluate two vaccine leads utilizing a sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27466db8ae8b4532e40612e5d44b512d
http://edoc.mdc-berlin.de/22013/7/22013suppl.zip
http://edoc.mdc-berlin.de/22013/7/22013suppl.zip
Autor:
Aileen, Ebenig, Samada, Muraleedharan, Julia, Kazmierski, Daniel, Todt, Arne, Auste, Martina, Anzaghe, André, Gömer, Dylan, Postmus, Patricia, Gogesch, Marc, Niles, Roland, Plesker, Csaba, Miskey, Michelle, Gellhorn Serra, Angele, Breithaupt, Cindy, Hörner, Carina, Kruip, Rosina, Ehmann, Zoltan, Ivics, Zoe, Waibler, Stephanie, Pfaender, Emanuel, Wyler, Markus, Landthaler, Alexandra, Kupke, Geraldine, Nouailles, Christine, Goffinet, Richard J P, Brown, Michael D, Mühlebach
Publikováno v:
Cell reports. 40(7)
Vaccine-associated enhanced respiratory disease (VAERD) is a severe complication for some respiratory infections. To investigate the potential for VAERD induction in coronavirus disease 2019 (COVID-19), we evaluate two vaccine leads utilizing a sever
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0d7e364410a511deb8eecbe2e71a7642
https://pubmed.ncbi.nlm.nih.gov/35952673
https://pubmed.ncbi.nlm.nih.gov/35952673
Autor:
Aileen Ebenig, Samada Muraleedharan, Julia Kazmierski, Daniel Todt, Arne Auste, Martina Anzaghe, André Gömer, Dylan Postmus, Patricia Gogesch, Marc Niles, Roland Plesker, Csaba Miskey, Michelle Gellhorn Serra, Angele Breithaupt, Cindy Hörner, Carina Kruip, Rosina Ehmann, Zoltan Ivics, Zoe Waibler, Stephanie Pfaender, Emanuel Wyler, Markus Landthaler, Alexandra Kupke, Geraldine Nouailles, Christine Goffinet, Richard J.P. Brown, Michael D. Mühlebach
Since December 2019, the novel human coronavirus SARS-CoV-2 has spread globally, causing millions of deaths. Unprecedented efforts have enabled development and authorization of a range of vaccines, which reduce transmission rates and confer protectio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0ee66773573f04284c10a648f85bc97
https://doi.org/10.1101/2021.12.28.474359
https://doi.org/10.1101/2021.12.28.474359
Autor:
Alexandra Kupke, Cornelius Rohde, Michelle Gellhorn-Serra, Lucie Sauerhering, Nico Becker, Anke Werner, Henning Gruell, Florian Klein, Falk Liberta, Markus Eickmann, Joerg C. Schmidt, Marek Widera, Stephan Becker, Zheng Cai, Sandra Ciesek, Guangwei Yang, Lennart Kaemper, Sandro Halwe, Felix Schiele, Michael Kluever, Manuel Koch, David Young, Verena Kraehling, Christoph Kreer, Matthias Zehner, Kanika Vanshylla, Fei Han, Michael S Marlow
Publikováno v:
Viruses
Volume 13
Issue 8
Viruses, Vol 13, Iss 1498, p 1498 (2021)
Volume 13
Issue 8
Viruses, Vol 13, Iss 1498, p 1498 (2021)
Despite recent availability of vaccines against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2), there is an urgent need for specific anti-SARS-CoV-2 drugs. Monoclonal neutralizing antibodies are an important drug class in the globa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::952ced4b49d33f4acbf6acd4cafe319d
https://doi.org/10.3390/v13081498
https://doi.org/10.3390/v13081498